Penumbra (PEN)
(Delayed Data from NYSE)
$203.53 USD
+2.00 (0.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $203.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$203.53 USD
+2.00 (0.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $203.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
GMED or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Don't Overlook These Top Medical Stocks as Q1 Earnings Approach
by Shaun Pruitt
Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
by Zacks Equity Research
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
GMED vs. PEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?
Here's Why Penumbra (PEN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
by Zacks Equity Research
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
Penumbra (PEN) Q4 Earnings Beat Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 7.04% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -17.39% and 3.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes
by Zacks Equity Research
Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Centene (CNC) Stock For Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
Integer Holdings Corporation (ITGR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.
Why You Should Invest in Encompass Health (EHC) Stock for Now
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.